воскресенье, 26 февраля 2017 г.

Cann Reaffirms Outperform Rating for Amgen, Inc.

Cann Reaffirms Outperform Rating for Amgen, Inc.


Several other analysts have also commented on AMGN. Argus set a $195.00 price target on shares of Amgen and gave the company a "buy" rating in a research report on Saturday, February 11th.



from Biotech News